Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
QVfhYu2vtEDF7ReV
